Skip to main content
. 2022 Mar 7;13:832589. doi: 10.3389/fphar.2022.832589

TABLE 1.

Antagonist activities of lipidated αCGRP8-37 analogues at calcitonin-family receptors expressed in Cos-7 cells or SK-N-MC cells with endogenous CGRP receptor expression.

αCGRP8-37 αCGRP7-37-palmitate V8C-palmitate K24C-palmitate K35C-palmitate
CGRPr (pKB) 9.09 ± 0.16 (5) 8.78 ± 0.06 (4) 9.35 ± 0.17 (5) 8.58 ± 0.25 (5) 7.24 ± 0.20 (5) a
AMY1r (pKB) 7.12 ± 0.13 (5) 8.80 ± 0.18 (5) a 8.26 ± 0.21 (5) a 8.75 ± 0.10 (5) a 6.01 ± 0.12 (5) a
AM1r (pA2) 7.36 ± 0.11 (9) 8.53 ± 0.17 (5) a 8.73 ± 0.17 (5) a 9.23 ± 0.16 (5) a 6.30 ± 0.14 (5) a
AM2r (pA2) 7.32 ± 0.20 (9) 8.55 ± 0.16 (5) a 8.18 ± 0.13 (5) b 9.18 ± 0.18 (5) a 6.60 ± 0.21 (5) b
CTr (pA2) c 7.11 ± 0.10 (5) 6.85 ± 0.13 (5) 6.21 ± 0.19 (5) 5.39 ± 0.30 (3) d
SK-N-MC (pA2) 9.58 ± 0.15 (6) 10.50 ± 0.19 (5) e 10.45 ± 0.24 (5) e 10.14 ± 0.17 (5) 7.78 ± 0.25 (5) a

Values are mean ± SEM of (n) independent experiments. pKB or pA2 comparisons to αCGRP8-37 were analyzed by one-way ANOVA followed by Dunnett’s multiple comparison test.

a

p < 0.001.

b

p < 0.05

c

αCGRP8-37 was too weak to generate a pA2 in the pilot experiments and sCT8-32 was used as a positive control for the CT receptor.

d

Denotes that five experiments were conducted but only (n) repeats elicited measurable pA2 values.

e

p < 0.01